- Home
- UGRO vs INDP Comparison
UGRO vs INDP Comparison
Compare UGRO & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UGRO
- INDP
- Stock Information
- Founded
- UGRO 2014
- INDP 2000
- Country
- UGRO United States
- INDP United States
- Employees
- UGRO N/A
- INDP N/A
- Industry
- UGRO Industrial Specialties
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- UGRO Consumer Discretionary
- INDP Health Care
- Exchange
- UGRO Nasdaq
- INDP Nasdaq
- Market Cap
- UGRO 18.0M
- INDP 15.4M
- IPO Year
- UGRO N/A
- INDP N/A
- Fundamental
- Price
- UGRO $1.43
- INDP $1.27
- Analyst Decision
- UGRO Strong Buy
- INDP Strong Buy
- Analyst Count
- UGRO 2
- INDP 1
- Target Price
- UGRO $5.63
- INDP $12.00
- AVG Volume (30 Days)
- UGRO 22.2K
- INDP 21.5K
- Earning Date
- UGRO 11-07-2024
- INDP 11-04-2024
- Dividend Yield
- UGRO N/A
- INDP N/A
- EPS Growth
- UGRO N/A
- INDP N/A
- EPS
- UGRO N/A
- INDP N/A
- Revenue
- UGRO $70,320,066.00
- INDP N/A
- Revenue This Year
- UGRO $14.76
- INDP N/A
- Revenue Next Year
- UGRO $21.29
- INDP N/A
- P/E Ratio
- UGRO N/A
- INDP N/A
- Revenue Growth
- UGRO 12.08
- INDP N/A
- 52 Week Low
- UGRO $1.02
- INDP $1.03
- 52 Week High
- UGRO $2.84
- INDP $3.25
- Technical
- Relative Strength Index (RSI)
- UGRO 53.40
- INDP 47.18
- Support Level
- UGRO $1.34
- INDP $1.10
- Resistance Level
- UGRO $1.55
- INDP $1.22
- Average True Range (ATR)
- UGRO 0.09
- INDP 0.12
- MACD
- UGRO 0.01
- INDP 0.01
- Stochastic Oscillator
- UGRO 63.48
- INDP 66.67
About UGRO urban-gro Inc.
Urban-gro Inc is an integrated professional services and construction design-build firm. Its business focuses predominantly on providing fee-based knowledge-based services as well as the value-added reselling of equipment. The company offers value-added architectural, engineering, systems procurement and integration, and construction design-build solutions to customers operating in the controlled environment agriculture (CEA) and industrial and other commercial (Commercial) sectors. It derives revenue predominately from the sale of equipment systems, services, construction design-build, and other various immaterial contracts with customers.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.